Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.

Abstract:

:Pharmacogenetics has been driven by a candidate gene approach. The disadvantage of this approach is that is limited by our current understanding of the mechanisms by which drugs act. Gene expression could help to elucidate the molecular signatures of antipsychotic treatments searching for dysregulated molecular pathways and the relationships between gene products, especially protein-protein interactions. To embrace the complexity of drug response, machine learning methods could help to identify gene-gene interactions and develop pharmacogenetic predictors of drug response. The present review summarizes the applicability of the topics presented here (gene expression, network analysis and gene-gene interactions) in pharmacogenetics. In order to achieve this, we present an example of identifying genetic predictors of extrapyramidal symptoms induced by antipsychotic.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Mas S,Gassó P,Lafuente A

doi

10.2217/pgs.15.134

subject

Has Abstract

pub_date

2015-11-01 00:00:00

pages

1975-88

issue

17

eissn

1462-2416

issn

1744-8042

journal_volume

16

pub_type

杂志文章,评审
  • Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.

    abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.14.52

    authors: Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

    更新日期:2014-05-01 00:00:00

  • Genetic determinants of warfarin dosing in the Han-Chinese population.

    abstract:UNLABELLED:Warfarin, a widely prescribed oral anticoagulant, is used for the prevention of thromboembolism. Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements. However, it is likely that other genes could also affect warfarin dose. AIMS:In this study, we aimed to identi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.106

    authors: Lee MT,Chen CH,Chou CH,Lu LS,Chuang HP,Chen YT,Saleem AN,Wen MS,Chen JJ,Wu JY,Chen YT

    更新日期:2009-12-01 00:00:00

  • A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention.

    abstract::Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0118

    authors: Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

    更新日期:2020-01-01 00:00:00

  • Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.

    abstract::Cancer patients frequently suffer from disease- and treatment-related pain, nausea and depression, which severely reduces patients' quality of life. It is critical that clinicians are aware of drug-gene interactions and recognize the utility of applying pharmacogenetic information to personalize and improve supportive...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.178

    authors: Andersen RL,Johnson DJ,Patel JN

    更新日期:2016-03-01 00:00:00

  • The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.

    abstract::The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.2.107

    authors: Hoffmann MM,Winkelmann BR,Wieland H,März W

    更新日期:2001-05-01 00:00:00

  • Identification of gene signatures for prednisolone-induced metabolic dysfunction in collagen-induced arthritic mice.

    abstract:BACKGROUND:Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. Little is known about the long-term effects of GCs on gene-expression in vivo during inflammation. AIM:Identify gene signatures underlying prednisolone-induced metabolic side effects in a co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.3

    authors: Ellero-Simatos S,Fleuren WW,Bauerschmidt S,Dokter WH,Toonen EJ

    更新日期:2014-04-01 00:00:00

  • High-throughput genotyping assay approaches.

    abstract::High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.1.95

    authors: Kwok PY

    更新日期:2000-02-01 00:00:00

  • Gene-expression microarrays provide new prognostic and predictive tests for breast cancer.

    abstract::Wide availability of systemic therapy agents has led to a considerable decline in mortality from breast cancer. However, the biology of breast cancer remains poorly understood. Currently, highly accurate markers to predict prognosis and probability of response to a given systemic therapy on an individual basis are lac...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.10.1359

    authors: Gong Y,Symmans WF,Pusztai L

    更新日期:2007-10-01 00:00:00

  • Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

    abstract::The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.7.895

    authors: Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

    更新日期:2004-10-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients.

    abstract:AIM:Several HLA alleles have been associated with antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) in different populations; however, this has not been investigated in Mexican Mestizos (MM). Thus, the purpose of this preliminary study was to determine the association of HLA class I alleles wi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.135

    authors: Fricke-Galindo I,Martínez-Juárez IE,Monroy-Jaramillo N,Jung-Cook H,Falfán-Valencia R,Ortega-Vázquez A,Alonso-Vilatela ME,López-López M

    更新日期:2014-01-01 00:00:00

  • Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation.

    abstract::The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.3.203

    authors: Huang S

    更新日期:2001-08-01 00:00:00

  • Adducin polymorphisms and the treatment of hypertension.

    abstract::Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in h...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.5.465

    authors: Manunta P,Citterio L,Lanzani C,Ferrandi M

    更新日期:2007-05-01 00:00:00

  • Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

    abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.3.217

    authors: Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

    更新日期:2007-03-01 00:00:00

  • Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

    abstract::In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.50

    authors: Korol S,Hurlimann T,Godard B,de Denus S

    更新日期:2013-04-01 00:00:00

  • Pharmacogenetics in clinical practice: how far have we come and where are we going?

    abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.52

    authors: Johnson JA

    更新日期:2013-05-01 00:00:00

  • Genomic architecture of pharmacological efficacy and adverse events.

    abstract::The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.144

    authors: Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

    更新日期:2014-12-01 00:00:00

  • Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity.

    abstract::RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.2.187

    authors: Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

    更新日期:2000-05-01 00:00:00

  • Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

    abstract:AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.247

    authors: Brandl EJ,Tiwari AK,Chowdhury NI,Zai CC,Lieberman JA,Meltzer HY,Kennedy JL,Müller DJ

    更新日期:2014-03-01 00:00:00

  • BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence.

    abstract:AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.96

    authors: Iamjan SA,Thanoi S,Watiktinkorn P,Nudmamud-Thanoi S,Reynolds GP

    更新日期:2015-01-01 00:00:00

  • The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.

    abstract::Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.84

    authors: Reed K,Parissenti AM

    更新日期:2011-10-01 00:00:00

  • Information management systems for pharmacogenomics.

    abstract::The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.5.651

    authors: Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

    更新日期:2002-09-01 00:00:00

  • Applications of biochip and microarray systems in pharmacogenomics.

    abstract::A DNA microarray system is usually comprised of DNA probes formatted on a microscale on a glass surface (chip), plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyse the data (bioinformatic tools). Biochips are formed by in situ (on chip) synthesis of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.3.289

    authors: Jain KK

    更新日期:2000-08-01 00:00:00

  • Genelex Corporation.

    abstract::Comprehensive, personalized medication management and pharmacogenetic testing are important existing opportunities to reduce adverse medication events and improve overall healthcare outcomes. A primary barrier to the adoption of personalized pharmacology is the inadequacy of existing patient records, drug interaction ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.4.469

    authors: Coleman H,Ashcraft K

    更新日期:2008-04-01 00:00:00

  • History repeats itself: the family medication history and pharmacogenomics.

    abstract::Related to many drug gene-product interactions, application of pharmacogenomics can lead to improved medication efficacy while decreasing or avoiding adverse drug reactions. However, utilizing pharmacogenomics without other information does not allow for optimal medication therapy. Currently, there is a lack of docume...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2015-0015

    authors: Smith TR,Kearney E,Hulick PJ,Kisor DF

    更新日期:2016-05-01 00:00:00

  • Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.

    abstract::Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to evaluate the progress in pharmacogenomics education since then, and to put forward further recommendations. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions around the world. Resu...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0009

    authors: Karas Kuželički N,Prodan Žitnik I,Gurwitz D,Llerena A,Cascorbi I,Siest S,Simmaco M,Ansari M,Pazzagli M,Di Resta C,Brandslund I,Schwab M,Vermeersch P,Lunshof JE,Dedoussis G,Flordellis CS,Fuhr U,Stingl JC,van Schaik RH

    更新日期:2019-06-01 00:00:00

  • microRNA expression changes after atrial fibrillation catheter ablation.

    abstract::Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.117

    authors: Sardu C,Santamaria M,Paolisso G,Marfella R

    更新日期:2015-11-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00

  • Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.

    abstract:AIM:Pharmacogenetic landscapes of commonly used antiplatelet drugs, warfarin and clopidogrel have been studied in-depth in many countries. However, there is a paucity of data to understand their patterns in the Arab populations. MATERIALS & METHODS:We analyzed the whole exome sequencing datasets of 100 Qatar individua...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0130

    authors: Sivadas A,Sharma P,Scaria V

    更新日期:2016-11-01 00:00:00

  • Pharmacogenomic biomarkers for personalized medicine.

    abstract::Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biom...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.75

    authors: Chen JJ,Lin WJ,Chen HC

    更新日期:2013-06-01 00:00:00